首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1425078

披衣菌感染感染診斷市場 – 2024 年至 2029 年預測

Chlamydia Infection Diagnostics Market - Forecasts from 2024 to 2029

出版日期: 2024年01月23日 | 出版商:

Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年披衣菌感染感染診斷市場規模為1211,526,000美元。

披衣菌感染診斷是確認個體中是否有披衣菌感染衣原體細菌的測試和治療。披衣菌感染是一種性行為感染疾病，並且無症狀性，因此即使您沒有表現出披衣菌感染症狀，您仍然可能被感染。因此，披衣菌感染的早期診斷和早期治療非常重要。

披衣菌感染感染診斷市場的推動要素

影響披衣菌感染感染診斷市場成長的主要因素是測試頻率的增加以及快速可靠測試的需求的增加。分子診斷在披衣菌感染感染診斷產業中勢頭強勁。它提供了多種技術優勢，包括快速的照護現場檢測選項，以滿足不斷成長的需求。此外，各種政府措施也促進了披衣菌感染感染診斷市場的成長。例如，英國政府的國家披衣菌感染篩檢計畫（NCSP）。

性行為感染傳染病的流行

沙眼衣原體感染正在迅速增加。這種增加的主要原因是性行為的變化以及個人對披衣菌感染本質上是性傳染病的認知缺乏。如果不及時治療，披衣菌感染會影響人體並導致嚴重的健康併發症。因此，對準確、及時診斷的需求顯著增加。此外，越來越需要新的診斷方法來治療抗抗生素的披衣菌感染菌株。在此背景下，披衣菌感染感染診斷產業的公司正在專注於新產品的開發。

披衣菌感染感染增加

由於個人意識的缺乏和性行為的改變，沙眼衣原體感染的人數正在顯著增加。例如，根據 CDC 2021 年發布的資料，報告了 1,644,416 例披衣菌感染病例，使其成為美國最受歡迎的疾病之一。這意味著2020年美國每10萬人中有495.5例。這種疾病的發生率不斷上升，增加了先進測試在診斷和治療中的使用，預計將推動披衣菌感染感染診斷市場的成長。

全球機構的支持不斷增加

根據世界衛生組織2020年發布的報告，世界衛生組織計畫減少全球性傳染感染的流行。正因為如此，披衣菌感染的診斷和治療顯著增加。此外，各議會和大學正在努力促進各種性傳染病的診斷和治療，尤其披衣菌感染，這種疾病對女性的身體有長期影響。如果及早診斷，披衣菌感染很容易治療。世界各地正在採取各種政府措施來根除披衣菌感染病例。

核酸增幅檢查(NAAT) 日益普及

核酸增幅檢查是一種檢測 DNA 的分子檢驗。為了診斷披衣菌感染感染，NAAT 檢測生物樣本中的披衣菌感染衣原體 RNA 或 DNA。 NAAT 方法更靈敏和特異性，適用於女性陰道拭子和男性和女性尿液。此外，2022 年 3 月，Binx Health IO CT/N 檢測獲得 FDA核准，可用於各種最終用戶的照護現場環境。產品核可進一步加強了 NAAT 在披衣菌感染感染診斷市場的地位。

先進診斷技術的開發

分子診斷測試等各種新興診斷技術的發展是推動披衣菌感染感染診斷市場的主要因素之一。這導致了各種準確且靈敏的披衣菌感染診斷測試的發展。例如，羅氏與 NICE 合作推出了披衣菌感染診斷的分子診斷指南。這些指南有助於英國診斷測試的標準化。全球醫療保健支出的增加帶來了各種投資，包括技術先進的診斷設施。

擴大在醫院的應用

醫院佔據披衣菌感染診斷市場的最大佔有率。便捷的基礎設施和合格的醫生是這項發展的主要成長要素。需要醫院診斷的大量患者以及在醫院輕鬆獲得披衣菌感染篩檢測試正在刺激披衣菌感染診斷市場的成長。此外，由於披衣菌感染衣原體分子診斷的應用（包括NAAT的應用）的快速增加，因此預計診斷中心也將顯著成長。

在北美，披衣菌感染感染診斷市場預計將穩定成長。

預計北美地區將在披衣菌感染感染診斷市場中佔據主要佔有率。披衣菌感染感染盛行率的不斷上升以及主要製造商的新產品創新將推動該地區的披衣菌感染感染診斷產業。例如，根據 CDC 的數據，2021 年美國約有 160 萬人感染披衣菌感染。此外，不斷增加的產品創新和核准正在推動該地區披衣菌感染感染診斷市場的快速成長。 2022 年 5 月，雅培的 Alinity m STI 檢測獲得 FDA核准。 Alinity m STI 需要單一拭子樣本或尿液樣本來診斷披衣菌感染。

Chlamydia diagnostics are tests and procedures used to identify the chlamydia trachomatis bacteria's presence in an individual. It is a sexually transmitted disease and is asymptomatic, which means the symptoms of chlamydia are not seen but the person can still be infected. Therefore, early diagnosis and treatment of chlamydia disease is important.

Driving factors for the chlamydia infection diagnostics market

The major factor influencing the growth of the chlamydia infection diagnostics market is the rising testing frequency and the increase in demand for quick and reliable testing. Molecular diagnostics have experienced a huge surge in the chlamydia infection diagnostics industry. To meet the rising demand there have been various technological advantages, including quick and point-of-care testing options. Further, various government initiatives are also fueling the chlamydia infection diagnostics market growth. For instance, the National Chlamydia Screening Program (NCSP) by the government of the United Kingdom.

Growing prevalence of sexually transmitted disease

Chlamydia infection has been growing at a rapid pace. This growth is majorly due to changing sexual behaviour and the lack of awareness of STDs essentially chlamydia among individuals. If chlamydia is untreated, it can affect the human body and cause serious health complications. Therefore, the demand for accurate and timely diagnosis is significantly increasing. Additionally, the need for novel diagnostic approaches to treat antibiotic-resistant strains to treat chlamydia bacteria has increased. Owing to this various chlamydia infection diagnostics industry players are focusing on new product development.

Increase in people suffering from chlamydia infection

There has been significant growth in people suffering from chlamydia infection owing to the lack of awareness among individuals and changing sexual behavior. For instance, as per the CDC data published in 2021, 1,644,416 cases of chlamydia were reported, making it one of the most prevalent diseases in the United States. This signifies that there were 495.5 cases per 100,000 people in the United States in 2020. The growing rate of this disease is increasing the diagnosis and treatment with the use of advanced tests and is expected to fuel the chlamydia infection diagnostics market growth.

Rising global agency support

According to the report published by The WHO in the year 2020, the agency plans to reduce the STI prevalence around the globe. Owing to this, the diagnosis and treatment for chlamydia has increased significantly. Furthermore, various councils and colleges have been focusing on promoting the diagnosis and treatment of various STDs especially chlamydia, which has a long-term effect on the female body. If chlamydia is diagnosed at an earlier stage it can be treated easily. Various government initiatives have been taking place to eradicate the cases of chlamydia globally.

Growing popularity of the Nucleic Acid Amplification Test (NAAT)

The Nucleic Acid Amplification Test is a molecular test that detects DNA. To diagnose chlamydia infection NAAT detects chlamydia trachomatis RNA or DNA in biological sample. The NAAT method is more sensitive and specific, and it's performed on vaginal swabs from women and urine for both males and females. Additionally, in March 2022, the Binx Health IO CT/N assay was approved by the FDA at point-of-care settings in various end users. Product approvals further increase the prominence of NAAT in the chlamydia infection diagnostics market

Development of advanced diagnostic technologies

The development of various advanced diagnostic technologies like molecular diagnostic tests is one of the key factors fueling the chlamydia infection diagnostics market. This has led to the development of various accurate and sensitive chlamydia diagnostic tests. For instance, Roche collaborated with NICE to introduce guidelines for molecular diagnostic usage for the diagnosis of chlamydia. These guidelines have helped diagnostic tests to be standardized in the United Kingdom. The increasing healthcare expenditure globally is leading to various investments, including technologically advanced diagnostic facilities.

Proliferating applications in hospitals

Hospitals are anticipated to hold the maximum chlamydia infection diagnostics market share. The effortless accessibility of infrastructure and qualified physicians are the key growth drivers for this development. There are huge numbers of patients who require diagnosis in hospitals and the easy availability of screening tests in hospitals to detect chlamydia is fueling the chlamydia infection diagnostics market growth. Moreover, diagnostic centers are also anticipated to grow significantly due to the surging application of molecular diagnosis of chlamydia trachomatis including the application of NAAT.

In North America, it is projected that the chlamydia infection diagnostics market will grow steadily.

The North American region is anticipated to secure a sizable chlamydia infection diagnostics market share. The regional chlamydia infection diagnostics industry will be fueled by the increasing prevalence of chlamydia infection and new product innovation by key manufacturers. For instance, according to the CDC, nearly 1.6 million people in the United States were infected with chlamydia in 2021. Furthermore, the increasing product innovation and approvals are surging the growth of the chlamydia infection diagnostics market in the region. In May 2022, Abbott's Alinity m STI assay received approval from the FDA. Alinity m STI requires one swab sample or urine sample to diagnose chlamydia.

Market Key Developments

In May 2023, The Visby Medical Sexual Health Test, a polymerase chain reaction (PCR) diagnostic test for the identification of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in women, has been approved by the Food and Drug Administration (FDA).
In May 2022, BD introduced the BD COR MX instrument which is an automated high-throughput molecular diagnostic platform in the United States.
In April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) collaborated with Visby Medical Inc., and The Body Agency Collective to improve STD diagnosis and treatment including chlamydia.

Segmentation:

By Product Type

Diagnostics
Therapeutics

By Test Type

Culture Tests
Nucleic Acid Amplification Test
Direct Fluorescent Antibody Test
Serology Tests
Others

By End-User

Hospitals
Diagnostic Centers
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY PRODUCT TYPE

5.1. Introduction
5.2. Diagnostics
5.3. Therapeutics

6. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY TEST TYPE

6.1. Introduction
6.2. Culture Tests
6.3. Nucleic Acid Amplification Test
6.4. Direct Fluorescent Antibody Test
6.5. Serology Tests
6.6. Others

7. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Diagnostic Centers
7.4. Others

8. CHLAMYDIA INFECTION DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others